REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Optimapharm Sp. z o.o. (Poland)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)
Secondary Activities: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Full name: Optimapharm Sp. z o.o. Profile Updated: May 01, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English & Polish Download a sample report

Optimapharm Sp. z o.o. is an enterprise in Poland, with the main office in Krakow. It operates in the Research and Development in Biotechnology (except Nanobiotechnology) industry. Optimapharm Sp. z o.o. was incorporated on August 26, 2019. The company’s latest financial report indicates a net sales revenue increase of 53.2% in 2022. There was a total growth of 91.28% in Optimapharm Sp. z o.o.’s total assets over the same period. Optimapharm Sp. z o.o.’s net profit margin decreased by 1.05% in 2022.

Headquarters
Ul. Na Zjezdzie 11
Krakow; Malopolskie; Postal Code: 30-527

Contact Details: Purchase the Optimapharm Sp. z o.o. report to view the information.

Basic Information
Outstanding Shares:
Purchase the Optimapharm Sp. z o.o. report to view the information.
Registered Capital:
Purchase the Optimapharm Sp. z o.o. report to view the information.
Incorporation Date:
August 26, 2019
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Optimapharm Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
53.2%▲
Total operating revenue
53.2%▲
Operating profit (EBIT)
24.66%▲
Net Profit (Loss) for the Period
30.5%▲
Total assets
91.28%▲
Total equity
112.15%▲
Operating Profit Margin (ROS)
-2.34%▼
Net Profit Margin
-1.05%▼
Return on Equity (ROE)
-33.08%▼
Quick Ratio
0.04%▲
Cash Ratio
0.11%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo